Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223.
作者信息
Viani Gustavo
机构信息
Head of the Radiotherapy Service, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. Email:
出版信息
Radiol Bras. 2023 May-Jun;56(3):VII-VIII. doi: 10.1590/0100-3984.2023.56.3e2.
Abstract
摘要
相似文献
1
Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223.镭-223治疗转移性去势抵抗性前列腺癌中总碱性磷酸酶的预后潜力洞察
Radiol Bras. 2023 May-Jun;56(3):VII-VIII. doi: 10.1590/0100-3984.2023.56.3e2.
2
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223.镭-223 治疗转移性去势抵抗性前列腺癌患者中早期碱性磷酸酶动力学作为生存标志物的研究
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3325-3334. doi: 10.1007/s00259-021-05283-6. Epub 2021 Mar 8.
3
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.镭-223 治疗转移性去势抵抗性前列腺癌患者的骨代谢生物标志物与生存的前瞻性评估：PRORADIUM 研究。
Eur Urol Oncol. 2024 Jun;7(3):447-455. doi: 10.1016/j.euo.2023.09.015. Epub 2023 Oct 12.
4
Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer.镭-223治疗去势抵抗性前列腺癌的四年临床经验。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Sep-Oct;38(5):298-304. doi: 10.1016/j.remn.2019.04.004. Epub 2019 Jul 28.
5
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer.循环肿瘤细胞作为生存和镭-223 治疗反应的生物标志物：转移性去势抵抗性前列腺癌患者队列的经验。
Clin Genitourin Cancer. 2018 Dec;16(6):e1133-e1139. doi: 10.1016/j.clgc.2018.07.013. Epub 2018 Jul 21.
6
Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study.镭-223 二氯化物治疗芬兰转移性去势抵抗性前列腺癌：真实世界证据多中心研究。
Cancer Med. 2023 Feb;12(4):4064-4076. doi: 10.1002/cam4.5262. Epub 2022 Sep 26.
7
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
8
Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report.去势抵抗性前列腺癌的组织病理学证实镭-223治疗期间骨转移的变化：一例报告。
Urol Case Rep. 2020 May 3;32:101230. doi: 10.1016/j.eucr.2020.101230. eCollection 2020 Sep.
9
Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.镭-223 治疗转移性去势抵抗性前列腺癌：台湾一家三甲医院真实世界应用的回顾性图表分析研究。
J Formos Med Assoc. 2022 Oct;121(10):1929-1937. doi: 10.1016/j.jfma.2022.01.020. Epub 2022 Feb 3.
10
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.机会性骨骼肌指标作为转移性去势抵抗性前列腺癌患者接受镭-223治疗的预后工具。
Ann Nucl Med. 2022 Apr;36(4):373-383. doi: 10.1007/s12149-022-01716-w. Epub 2022 Jan 19.
引用本文的文献
1
Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy.放射性镭治疗转移性去势抵抗性前列腺癌患者中前列腺特异抗原倍增时间的增加可预测生存。
Ann Nucl Med. 2024 Jul;38(7):508-515. doi: 10.1007/s12149-024-01924-6. Epub 2024 Apr 22.
本文引用的文献
1
Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study.镭-233治疗转移性去势抵抗性前列腺癌后总碱性磷酸酶的变化：一项单中心、真实世界的回顾性研究。
Radiol Bras. 2023 May-Jun;56(3):125-130. doi: 10.1590/0100-3984.2022.0080.
2
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.来自III期ALSYMPCA研究的二氯化镭-223的患者报告生活质量分析。
Ann Oncol. 2016 May;27(5):868-74. doi: 10.1093/annonc/mdw065. Epub 2016 Feb 23.
3
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.镭-223 二氯化物在有或无先前多西他赛治疗的去势抵抗性前列腺癌和有症状骨转移患者中的疗效和安全性：来自随机、双盲、III 期 ALSYMPCA 试验的预设亚组分析。
Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17.
4
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
5
NCCN clinical practice guidelines in oncology: prostate cancer.美国国立综合癌症网络（NCCN）肿瘤学临床实践指南：前列腺癌
J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. doi: 10.6004/jnccn.2010.0012.
Zotero 插件